[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548636":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":25,"locations":31,"responsibleParty":109,"collaborators":111,"id":114,"slug":115,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":116,"sex":122,"minAge":10,"maxAge":10,"enrollmentInfo":123,"targetDuration":10,"studyType":126,"phases":10,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},{"fullName":5,"class":6},"Amryt Pharma","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with dystrophic or junctional EB being treated with Filsuvez",null,"Patients in this cohort will be receiving treatment with Filsuvez for their EB.",[13],"Drug: Filsuvez",{"label":15,"type":10,"description":16,"interventionNames":10},"Patients with dystrophic or junctional EB not being treated with Filsuvez","Patients in this cohort will be receiving treatment other than Filsuvez or no treatment at all for their EB.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Filsuvez","Topical gel",[9],[24],"Birch bark extract",[26],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Chiesi Clinical Trials","CONTACT","+3905212791","clinicaltrials_info@chiesi.com",[32,51,67,83,93],{"facility":33,"status":34,"city":35,"state":10,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"CHU de Toulouse, Hôpital Larrey","RECRUITING","Toulouse","France","FR",{"type":39,"coordinates":40},"Point",[41,42],1.44367,43.60426,{"lat":42,"lon":41},[45,49],{"name":46,"role":28,"phone":47,"phoneExt":10,"email":48},"Juliette Mazereeuw Hautier","33 5 67 77 18 76","mazereeuw-hautier.j@chu-toulouse.fr",{"name":46,"role":50,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":52,"status":34,"city":53,"state":10,"zip":10,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Hospital of Skin and Venereal Diseases of Thessaloniki","Thessaloniki","Greece","GR",{"type":39,"coordinates":57},[58,59],22.93493,40.64072,{"lat":59,"lon":58},[62,66],{"name":63,"role":28,"phone":64,"phoneExt":10,"email":65},"Dimitra Kiritsi","0030-6983375771","dimkyritsi@auth.gr",{"name":63,"role":50,"phone":10,"phoneExt":10,"email":10},{"facility":68,"status":34,"city":69,"state":10,"zip":10,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Hospital Clinic, Barcelona","Barcelona","Spain","ES",{"type":39,"coordinates":73},[74,75],2.15899,41.38879,{"lat":75,"lon":74},[78,82],{"name":79,"role":28,"phone":80,"phoneExt":10,"email":81},"Josep Riera Monroig","93 227 54 00","jriera@clinic.cat",{"name":79,"role":50,"phone":10,"phoneExt":10,"email":10},{"facility":84,"status":34,"city":69,"state":10,"zip":10,"country":70,"countryCode":71,"cosmosGeoPoint":85,"geoPoint":87,"contacts":88},"Hospital San Juan de Dios (Barcelona)",{"type":39,"coordinates":86},[74,75],{"lat":75,"lon":74},[89,92],{"name":90,"role":28,"phone":10,"phoneExt":10,"email":91},"Asuncion Vicente","asuncion.vicente@sjd.es",{"name":90,"role":50,"phone":10,"phoneExt":10,"email":10},{"facility":94,"status":34,"city":95,"state":10,"zip":10,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Guy's and St Thomas' NHS Foundation Trust","London","United Kingdom","UK",{"type":39,"coordinates":99},[100,101],-0.12574,51.50853,{"lat":101,"lon":100},[104,108],{"name":105,"role":28,"phone":106,"phoneExt":10,"email":107},"Jemima Mellerio","44 20 7188 6399","jemima.mellerio@gstt.nhs.uk",{"name":105,"role":50,"phone":10,"phoneExt":10,"email":10},{"type":110,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[112],{"name":113,"class":6},"Chiesi Farmaceutici S.p.A.","100548636","a-study-to-assess-the-incidence-of-skin-cancers-in-patients-with-epidermolysis-bullosa-receiving-filsuvez-100548636",false,"NCT06423573","A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez","A Long-term Non-interventional Study to Assess the Incidence of Skin Malignancies in Patients With Dystrophic and Junctional Epidermolysis Bullosa Receiving Treatment With Filsuvez","FOSteR","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of dystrophic EB or junctional EB\n\nExclusion Criteria:\n\n* None","ALL",{"count":124,"type":125},580,"ESTIMATED","OBSERVATIONAL","In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at greatly increased risk of developing skin cancers. Filsuvez is a topical gel used to promote healing of skin lesions in patients with certain types of EB. In this observational study, patients with either dystrophic EB (DEB) or junctional EB (JEB) will receive standard of care treatment, whether Filsuvez or something else, and will be followed for up to 5 years. The main purpose is to see if the use of Filsuvez affects the likelihood of developing skin malignancies in these patient populations.",[129,130],"Epidermolysis Bullosa, Dystrophic","Epidermolysis Bullosa, Junctional",[20,24],"2025-09-18",{"date":134,"type":135},"2025-09-19","ACTUAL",{"date":137,"type":135},"2024-12-18",{"date":139,"type":125},"2032-08-01",{"name":5,"class":6},5]